

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

**Praemium Limited**

ABN

74 098 405 826

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |                                    |
|---|---|------------------------------------|
| 1 | +Class of +securities issued or to be issued  | Ordinary Shares                    |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued   |                                    |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares issued. |

**Appendix 3B**  
**New issue announcement**

---

<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>Yes. The new ordinary shares will rank equally with the existing ordinary shares in issue traded under ASX ticker code PPS.</p>
<p>5 Issue price or consideration</p>	<p>Nil.</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Conversion of Performance Rights to Shares for UK employees under the Praemium Directors &amp; Employees Benefits Plan.</p>
<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the +securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	<p>Yes.</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>Following approval by shareholders at the Company's AGM on 21 November 2017.</p>
<p>6c Number of +securities issued without security holder approval under rule 7.1</p>	<p>443,355 shares issued.</p>
<p>6d Number of +securities issued with security holder approval under rule 7.1A</p>	<p>Nil.</p>

---

+ See chapter 19 for defined terms.

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable					
6f	Number of +securities issued under an exception in rule 7.2	Nil.					
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	Not applicable					
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable					
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer Annexure A					
7	<p>+Issue dates</p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.</p>	7 December 2017					
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	<table border="1" style="width: 100%;"> <thead> <tr> <th style="width: 50%;">Number</th> <th style="width: 50%;">+Class</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;"><b>400,263,330</b></td> <td><b>399,819,975</b> existing fully paid ordinary shares, plus <b>443,355</b> new fully paid ordinary shares issued</td> </tr> </tbody> </table>	Number	+Class	<b>400,263,330</b>	<b>399,819,975</b> existing fully paid ordinary shares, plus <b>443,355</b> new fully paid ordinary shares issued	
Number	+Class						
<b>400,263,330</b>	<b>399,819,975</b> existing fully paid ordinary shares, plus <b>443,355</b> new fully paid ordinary shares issued						

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

	Number	+Class
9	Number and +class of all +securities not quoted on ASX ( <i>including</i> the +securities in section 2 if applicable)	11,851,977 Performance Rights & Options (see detailed table attached as attachment A)
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change in dividend policy.

**Part 2 - Pro rata issue**

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	+Class of +securities to which the offer relates	
15	+Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

---

+ See chapter 19 for defined terms.

- |    |   |  |
|----|---|--|
| 20 | Names of any underwriters   |  |
| 21 | Amount of any underwriting fee or commission  |  |
| 22 | Names of any brokers to the issue   |  |
| 23 | Fee or commission payable to the broker to the issue  |  |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders  |  |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting   |  |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled   |  |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders |  |
| 28 | Date rights trading will begin (if applicable)  |  |
| 29 | Date rights trading will end (if applicable)  |  |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker?  |  |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?   |  |

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 +Issue date

**Part 3 - Quotation of securities**

*You need only complete this section if you are applying for quotation of securities*

- 34 Type of +securities  
(tick one)
- (a)  +Securities described in Part 1
- (b)  All other +securities  
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

**Entities that have ticked box 34(a)**

**Additional securities forming a new class of securities**

*Tick to indicate you are providing the information or documents*

- 35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over
- 37  A copy of any trust deed for the additional +securities

**Entities that have ticked box 34(b)**

38 Number of +securities for which +quotation is sought

39 +Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)		

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

**Quotation agreement**

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



Company secretary

Date: 8 December 2017

Print name:

Paul Gutteridge



# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b><i>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</i></b>	
<b><i>Insert</i></b> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	397,140,525
<b><i>Add</i></b> the following: <ul style="list-style-type: none"> <li>• Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul> <b><i>Note:</i></b> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	2,937,018
<b><i>Subtract</i></b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil
<b>“A”</b>	400,077,543

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

<b>Step 2: Calculate 15% of “A”</b>	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply</b> “A” by 0.15	60,011,631
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><i>Insert</i> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	185,787
“C”	185,787
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
“A” x 0.15 <i>Note: number must be same as shown in Step 2</i>	60,011,631
<b>Subtract</b> “C” <i>Note: number must be same as shown in Step 3</i>	185,787
<b>Total</b> [“A” x 0.15] – “C”	59,825,844 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b> <i>Note: number must be same as shown in Step 1 of Part 1</i>	400,077,543
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10
<b>Multiply “A” by 0.10</b>	40,007,754
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• This applies to equity securities – not just ordinary securities</li> <li>• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	NIL
<b>“E”</b>	NIL
<b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>	
<b>“A” x 0.10</b> <i>Note: number must be same as shown in Step 2</i>	40,007,754
<b>Subtract “E”</b> <i>Note: number must be same as shown in Step 3</i>	NIL
<b>Total</b> [“A” x 0.10] – “E”	40,007,754 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.

**Attachment A- Part 1, Question 9**

Description (All issued pursuant to the Employee & Directors Benefits Plan)	Issue Date	Expiry Date	Issue Price	No on Register on 30 October 2017 (Date of this 3B)	Lapsed / Expired / Cancelled	Vested / Exercised	Allocations	No on Register on 8 December 2017 (Date of this 3B)
Performance rights (EMI Options (UK)) - nil exercise price Tranche 9 - Earliest Vest Date (subject to satisfaction of performance conditions)	23/12/2010	1/12/2020	Nil	33,333				33,333
Performance Rights (FY13-1) – nil exercise price – Vest on date of issue of FY13 Annual report (subject to satisfaction of performance conditions)	6/09/2012	1/12/2020	Nil	60,000				60,000
Performance Rights (FY14-1) – nil exercise price – Vest on date of issue of FY14 Annual report (subject to satisfaction of performance conditions)	11/09/2013	1/12/2022	Nil	10,000				10,000
Performance Rights (FY14-2) – nil exercise price – Vest on date of issue of FY15 Annual report (subject to satisfaction of performance conditions)	11/09/2013	1/12/2022	Nil	180,000				180,000
Performance Rights (FY14-3) – nil exercise price – Vest on date of issue of FY16 Annual report (subject to satisfaction of performance conditions)	11/09/2013	1/12/2022	Nil	400,000		(40,000)		360,000
Performance Rights (FY15-1) – nil exercise price – Vest on date of issue of FY15 Annual report (subject to satisfaction of performance conditions)	12/11/2014	31/12/2019	Nil	89,250		(7,500)		81,750
Performance Rights (FY15-2) – nil exercise price – Vest on date of issue of FY16 Annual report (subject to satisfaction of performance conditions)	12/11/2014	31/12/2019	Nil	160,500		(49,500)		111,000
Performance Rights (FY15-3) – nil exercise price – Vest on date of issue of FY17 Annual report (subject to satisfaction of performance conditions)	12/11/2014	31/12/2019	Nil	354,000		(142,000)		212,000
Performance Rights (FY16-1) – nil exercise price – Vest on date of issue of FY16 Annual report (subject to satisfaction of performance conditions)	15/09/2015	31/12/2020	Nil	109,109		(25,516)		83,593
Performance Rights (FY16-2) – nil exercise price – Vest on date of issue of FY17 Annual report (subject to satisfaction of performance conditions)	15/09/2015	31/12/2020	Nil	274,463	(2)	(103,348)		171,113
Performance Rights (FY16-3) – nil exercise price – Vest on date of issue of FY18 Annual report (subject to satisfaction of performance conditions)	15/09/2015	31/12/2020	Nil	1,506,600	(1,800)			1,504,800
Performance Rights (FY17-1) – nil exercise price – Vest on date of issue of FY17 Annual report (subject to satisfaction of performance conditions)	20/09/2016	31/12/2021	Nil	171,749		(75,491)		96,258
Performance Rights (FY17-2) – nil exercise price – Vest on date of issue of FY18 Annual report (subject to satisfaction of performance conditions)	20/09/2016	31/12/2021	Nil	839,220	(250)			838,970
Performance Rights (FY17-3) – nil exercise price – Vest on date of issue of FY19 Annual report (subject to satisfaction of performance conditions)	20/09/2016	31/12/2021	Nil	2,014,128	(600)			2,013,528
Performance Rights (FY18-1) – nil exercise price – Vest on date of issue of FY18 Annual report (subject to satisfaction of performance conditions)	20/09/2017	30/09/2018	Nil	1,400,000				1,400,000
Performance Rights (FY18-2) – nil exercise price – Vest on date of issue of FY18 Annual report (subject to satisfaction of performance conditions)	20/09/2017	31/12/2022	Nil	686,973	(2,128)		19,500	704,345
Performance Rights (FY18-3) – nil exercise price – Vest on date of issue of FY19 Annual report (subject to satisfaction of performance conditions)	20/09/2017	31/12/2022	Nil	1,144,954	(3,546)		32,500	1,173,908
Performance Rights (FY18-4) – nil exercise price – Vest on date of issue of FY20 Annual report (subject to satisfaction of performance conditions)	20/09/2017	31/12/2022	Nil	2,747,890	(8,511)		78,000	2,817,379
<b>Performance Rights (including EMI Options) Totals:</b>				<b>12,182,169</b>	<b>(16,837)</b>	<b>(443,355)</b>	<b>130,000</b>	<b>11,851,977</b>
<b>Number of securities on issue that are not quoted</b>				<b>12,182,169</b>	<b>(16,837)</b>	<b>(443,355)</b>	<b>130,000</b>	<b>11,851,977</b>